Meeting
2020 ASCO Virtual Scientific Program
Pan-tumor analyses of kinase fusions detected in circulating tumor DNA (ctDNA) and concordance with paired tissue.
Authors
Jessica Kim Lee
Foundation Medicine, Inc., Cambridge, MA
Jessica Kim Lee , Daniel Lieber , Russell Madison , Jon Chung , Alexa Betzig Schrock , James Creeden , Jeffrey Venstrom , Brian Michael Alexander , Mehlika Hazar-Rethinam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3517)
DOI
10.1200/JCO.2020.38.15_suppl.3517
Abstract #
3517
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A cell-free RNA-based next-generation sequencing (NGS) assay for the detection of actionable gene fusions in patients with non–small cell lung cancer (NSCLC).
First Author: Yukti Choudhury
Poster
2018 ASCO Annual Meeting
Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).
First Author: Ben C. Creelan
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu